Commentary: SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

Serena Di Cosimo¹, Luca Porcu², Andrea Malfettone³, Javier Cortés^{3

4

5

6

7}, Rosalba Miceli⁸

Affiliations

¹ Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
² Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
³ Medica Scientia Innovation Research (MedSIR), New Jersey, United States.
⁴ Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
⁵ IOB Institute of Oncology, Quiron Group, Madrid, Spain.
⁶ IOB Institute of Oncology, Quiron Group, Barcelona, Spain.
⁷ Vall d'Hebron Insititute of Oncology (VHIO), Barcelona, Spain.
⁸ Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Comment

Serena Di Cosimo et al. Front Oncol. 2020.

. 2020 Jul 10:10:1223.

doi: 10.3389/fonc.2020.01223. eCollection 2020.

Serena Di Cosimo¹, Luca Porcu², Andrea Malfettone³, Javier Cortés^{3

4

5

6

7}, Rosalba Miceli⁸

¹ Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
² Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
³ Medica Scientia Innovation Research (MedSIR), New Jersey, United States.
⁴ Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
⁵ IOB Institute of Oncology, Quiron Group, Madrid, Spain.
⁶ IOB Institute of Oncology, Quiron Group, Barcelona, Spain.
⁷ Vall d'Hebron Insititute of Oncology (VHIO), Barcelona, Spain.
⁸ Clinical Epidemiology and Trial Organization Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

No abstract available

Keywords: COVID-19; SARS-CoV-2 infection; cancer care; patient guidance; risk factors.

Comment on

SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.
Yu J, Ouyang W, Chua MLK, Xie C. Yu J, et al. JAMA Oncol. 2020 Jul 1;6(7):1108-1110. doi: 10.1001/jamaoncol.2020.0980. JAMA Oncol. 2020. PMID: 32211820 Free PMC article.

1. Reportof the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available online at: https://www.who.int/publications-detail/report-of-the-who-china-joint-mi... (accessed April 27, 2020).
1. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. JAMA Oncol. (2020) 10.1001/jamaoncol.2020.0980 - DOI - PMC - PubMed
1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. . Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. (2020) 323:1061–69. 10.1001/jama.2020.1585 - DOI - PMC - PubMed
1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. (2020) 382:1708–20. 10.1056/NEJMoa2002032 - DOI - PMC - PubMed
1. Characteristics of COVID-19 Patients Dying in Italy Report Based on available data on March 20th 2020. Available online at: https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20... (accessed April 25, 2020).